| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Overexpression of S100A4 is frequently found in pancreatic and lung cancers. Knockdown suppresses cell growth and forced expression promotes cell motility in both of the cancer types. Furthermore, we analyzed primary resected pancreatic cancer tissues immunohistochemically and found positive association between overexpression of S100A4 and tumor cell invasion, particularly to nerves. Microarray analyses after forced expression in S100A4-low expressing cells identified candidate downstream genes and we are now analyzing functions of these genes.
Because overexpression of S100A4 and poor prognoses after gemcitabine treatment was reported in pancreatic cancer, we established 8 cancer cell lines with acquired gemcitabine resistance; these include four pancreatic, one gastric, one colon, one gallbladder, one bile duct cancers. Frequent inactivating mutation in deoxycytidine kinase was observed, and further investigation is on the way.
|
